Optimizing Prostate Cancer Monitoring with PRECISE v2

Active Surveillance and MRI Integration

Active surveillance provides a safe alternative to immediate surgery for many men with low-risk prostate cancer. Consequently, the PRECISE version 2 criteria have emerged as a vital tool for monitoring these patients. This framework helps radiologists detect clinically significant progression while minimizing unnecessary biopsies. Therefore, medical teams can offer personalized care based on objective imaging data.

Implementing the PRECISE Version 2 Criteria

The updated system introduces a simplified 1-5 Likert scoring method for longitudinal evaluation. Furthermore, the criteria emphasize comparing current scans with both baseline and previous examinations. Specifically, the PRECISE 3 category now includes sub-divisions for visible and non-visible disease. Consequently, this distinction provides clearer communication between the radiology suite and the urology clinic. Additionally, radiologists must assess lesion size and appearance with strict adherence to these standardized rules. Notably, high-quality imaging remains a prerequisite for using this scoring system effectively. However, doctors should always integrate these MRI findings with clinical markers like PSA levels. Moreover, the focus remains on identifying new or enlarging lesions that might signal a need for treatment.

Improving Clinical Outcomes in India

Indian clinicians increasingly adopt these global standards to manage the growing burden of prostate cancer. Furthermore, the use of structured reporting reduces inter-observer variability among radiologists. This consistency is essential for long-term patient safety during surveillance. Consequently, patients receive more reliable advice regarding their disease status. In addition, the PRECISE version 2 criteria help avoid the complications associated with overtreatment. Finally, this evidence-based approach strengthens the multidisciplinary team’s ability to manage prostate health.

Frequently Asked Questions

Q1: What are the main changes in the PRECISE version 2 criteria?

The updated criteria introduce a more structured 1-5 Likert scale and sub-divide the stable disease category into visible and non-visible types. These changes improve the precision of longitudinal monitoring.

Q2: Who are the ideal candidates for monitoring under these guidelines?

Ideal candidates include men with low-risk or favorable intermediate-risk prostate cancer who wish to avoid immediate intervention. These patients undergo regular MRI scans to ensure the disease remains stable.

References

1. Ogata A et al. PRECISE Version 2: Essential Tips for Prostate Cancer Monitoring Using MRI. Radiographics. 2026 May undefined. doi: 10.1148/rg.250126. PMID: 42060486.
2. Englman C et al. PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer. European Urology. 2024 Sep;86(3):240-255.
3. Giganti F et al. Prostate cancer measurements on serial MRI during active surveillance: it’s time to be PRECISE. Br J Radiol. 2020;93(1116):20200819.